27 min read
Keypoint Newsletter: Welcoming the New Fellows Class of 2024
Keystone Symposia is pleased to introduce the Keystone Symposia Fellows Class of 2024! This year we welcome seven...
Dr. Corbett uses her viral immunology expertise to propel novel vaccine development for pandemic preparedness, including mRNA-1273, a leading vaccine against SARS-CoV-2. The vaccine concept incorporated in mRNA-1273 was designed by Dr. Corbett's NIH team from viral sequence and rapidly deployed to industry partner, Moderna, Inc., for Phase 1 clinical trial, which unprecedently began only 66 days from viral sequence release. mRNA-1273 was shown to be 94.1% effective in Phase 3 trial and is authorized for use in multiple countries. Alongside mRNA-1273, Dr. Corbett boasts a patent portfolio which also includes universal coronavirus and influenza vaccine concepts and novel therapeutic antibodies. In all, she has over 15 years of experience studying dengue virus, respiratory syncytial virus, influenza virus, and coronaviruses, garnering several prestigious awards, such as the Benjamin Franklin Next Gen Award and the Salzman Memorial Award in Virology. Combining her research goals with her knack for mentorship, Dr. Corbett invests much of her time in underserved communities as an advocator of STEM education and vaccine awareness.
Research Area(s):
ImmunologyResearch Keywords:
Mentor: Chris L. Karp, MD
Dec 4, 2023 by Keystone Symposia
Keystone Symposia is pleased to introduce the Keystone Symposia Fellows Class of 2024! This year we welcome seven...
Sep 6, 2023 by Keystone Symposia
Established in 2009, Keystone Symposia’s Fellows Program has become a premier professional advancement opportunity for...